As a central node within the RAS-MAPK signalling cascade, MEK represents a promising therapeutic target; however clinical studies of MEK inhibitors (MEKi) have shown only limited anti-tumour activity[24,25]. The gene discussed is MAP2K7; the disease is neoplasm.